Halozyme Therapeutics Inc (HALO)

11.39
0.47 3.96
NASDAQ : Health Care
Prev Close 11.86
Open 11.65
Day Low/High 11.28 / 12.11
52 Wk Low/High 6.96 / 25.00
Volume 2.19M
Avg Volume 2.12M
Exchange NASDAQ
Shares Outstanding 129.49M
Market Cap 1.54B
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Retail, Politics and Bonds Signal Trend Changes: Cramer's 'Mad Money' Recap (Thursday 1/5/17)

Retail, Politics and Bonds Signal Trend Changes: Cramer's 'Mad Money' Recap (Thursday 1/5/17)

Jim Cramer says this rally relies on a speedy end to regulation, fast repatriation of foreign money and corporate tax reform.

Halozyme Announces Phase 2 Study In Advanced Pancreas Cancer Meets Key Endpoints

Halozyme Announces Phase 2 Study In Advanced Pancreas Cancer Meets Key Endpoints

-Study shows statistically significant improvement in progression-free survival (PFS) in all evaluable patients and in patients with high levels of hyaluronan (HA), a potential new biomarker-

First Week Of HALO February 2017 Options Trading

First Week Of HALO February 2017 Options Trading

Investors in Halozyme Therapeutics Inc saw new options begin trading this week, for the February 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the HALO options chain for the new February 2017 contracts and identified one put and one call contract of particular interest.

Halozyme Therapeutics Reaches Analyst Target Price

Halozyme Therapeutics Reaches Analyst Target Price

In recent trading, shares of Halozyme Therapeutics Inc have crossed above the average analyst 12-month target price of $13.15, changing hands for $13.83/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Halozyme Announces Broad Clinical Collaboration Agreement To Evaluate PEGPH20 And Tecentriq In Up To Eight Tumor Types

Halozyme Announces Broad Clinical Collaboration Agreement To Evaluate PEGPH20 And Tecentriq In Up To Eight Tumor Types

Phase 1b/2 studies will evaluate Halozyme's investigational drug, PEGPH20 with Genentech's anti-PDL1 Tecentriq® (atezolizumab)

PEGPH20 Selected For Inclusion In Groundbreaking Clinical Trial Initiative Designed To Transform Outcomes For Pancreatic Cancer Patients

PEGPH20 Selected For Inclusion In Groundbreaking Clinical Trial Initiative Designed To Transform Outcomes For Pancreatic Cancer Patients

Pancreatic Cancer Action Network's Precision Promise Initiative to Incorporate Halozyme's PEGPH20 for Patients Identified With High Levels of Hyaluronan

Are Your Stocks Just Running in Place?

Are Your Stocks Just Running in Place?

If investing is like a horserace, you can change horses in the middle of the race.

Bullish & Bearish Reversals for the Week

Bullish & Bearish Reversals for the Week

Energy and consumer defensive names dominate on the bearish side.

Netflix Can Break out Soon

Netflix Can Break out Soon

Plus, charts from ALGN, HALO and CME.

One Reason Why Halozyme Therapeutics (HALO) Stock Is Climbing Today

One Reason Why Halozyme Therapeutics (HALO) Stock Is Climbing Today

Halozyme Therapeutics (HALO) stock price target was raised at Piper Jaffray on Friday due to the long-term value of its Enhanze products.

Eisai And Halozyme Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20

Eisai And Halozyme Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20

- Clinical trial explores whether or not eribulin in combination with PEGPH20 can improve overall response rate in women with advanced breast cancer -

These 5 Stocks Under $10 Are Set to Soar

These 5 Stocks Under $10 Are Set to Soar

Here's a technical look at how to trade five stocks trading for less than $10 a share.

Halozyme Therapeutics (HALO) Is Today's Dead Cat Bounce Stock

Halozyme Therapeutics (HALO) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Halozyme Therapeutics (HALO) as a "dead cat bounce" (down big yesterday but up big today) candidate

Today's Dead Cat Bounce Stock: Halozyme Therapeutics (HALO)

Today's Dead Cat Bounce Stock: Halozyme Therapeutics (HALO)

Trade-Ideas LLC identified Halozyme Therapeutics (HALO) as a "dead cat bounce" (down big yesterday but up big today) candidate

Halozyme Announces Agreement To Refinance Debt, Increases 2016 Guidance For Year-End Cash Balance

Halozyme Announces Agreement To Refinance Debt, Increases 2016 Guidance For Year-End Cash Balance

- Interest-only repayment provision results in $44 million increase to expected cash balance through 2017-

Today's Weak On High Volume Stock: Halozyme Therapeutics (HALO)

Today's Weak On High Volume Stock: Halozyme Therapeutics (HALO)

Trade-Ideas LLC identified Halozyme Therapeutics (HALO) as a weak on high relative volume candidate

Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20

Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20

- Data presented today at American Society of Clinical Oncology Annual Conference Supports Ongoing Phase 3 HALO 301 Clinical Study -

July 15th Options Now Available For Halozyme Therapeutics (HALO)

July 15th Options Now Available For Halozyme Therapeutics (HALO)

Investors in Halozyme Therapeutics Inc saw new options begin trading today, for the July 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the HALO options chain for the new July 15th contracts and identified one put and one call contract of particular interest.